COSCIENS Biopharma (CSCI) Competitors $2.95 -0.09 (-3.09%) As of 11:03 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrendsBuy This Stock CSCI vs. OKYO, VRCA, OTLK, ATNM, RPTX, IBIO, NBRV, KZR, SPRO, and CELUShould you be buying COSCIENS Biopharma stock or one of its competitors? The main competitors of COSCIENS Biopharma include OKYO Pharma (OKYO), Verrica Pharmaceuticals (VRCA), Outlook Therapeutics (OTLK), Actinium Pharmaceuticals (ATNM), Repare Therapeutics (RPTX), iBio (IBIO), Nabriva Therapeutics (NBRV), Kezar Life Sciences (KZR), Spero Therapeutics (SPRO), and Celularity (CELU). These companies are all part of the "pharmaceutical products" industry. COSCIENS Biopharma vs. OKYO Pharma Verrica Pharmaceuticals Outlook Therapeutics Actinium Pharmaceuticals Repare Therapeutics iBio Nabriva Therapeutics Kezar Life Sciences Spero Therapeutics Celularity COSCIENS Biopharma (NASDAQ:CSCI) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations, media sentiment and community ranking. Does the media refer more to CSCI or OKYO? In the previous week, OKYO Pharma had 3 more articles in the media than COSCIENS Biopharma. MarketBeat recorded 4 mentions for OKYO Pharma and 1 mentions for COSCIENS Biopharma. COSCIENS Biopharma's average media sentiment score of 1.87 beat OKYO Pharma's score of 1.44 indicating that COSCIENS Biopharma is being referred to more favorably in the media. Company Overall Sentiment COSCIENS Biopharma Very Positive OKYO Pharma Positive Do insiders and institutionals hold more shares of CSCI or OKYO? 0.7% of COSCIENS Biopharma shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 0.1% of COSCIENS Biopharma shares are held by company insiders. Comparatively, 40.5% of OKYO Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is CSCI or OKYO more profitable? OKYO Pharma has a net margin of 0.00% compared to COSCIENS Biopharma's net margin of -428.43%. OKYO Pharma's return on equity of 0.00% beat COSCIENS Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets COSCIENS Biopharma-428.43% -95.93% -45.66% OKYO Pharma N/A N/A N/A Which has better earnings & valuation, CSCI or OKYO? COSCIENS Biopharma has higher revenue and earnings than OKYO Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCOSCIENS Biopharma$7.60M1.46-$16.55M-$11.87-0.25OKYO PharmaN/AN/A-$16.83MN/AN/A Do analysts rate CSCI or OKYO? OKYO Pharma has a consensus price target of $7.00, suggesting a potential upside of 414.71%. Given OKYO Pharma's stronger consensus rating and higher possible upside, analysts clearly believe OKYO Pharma is more favorable than COSCIENS Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score COSCIENS Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00OKYO Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in CSCI or OKYO? OKYO Pharma received 10 more outperform votes than COSCIENS Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformCOSCIENS BiopharmaN/AN/AOKYO PharmaOutperform Votes10100.00% Underperform VotesNo Votes Which has more risk and volatility, CSCI or OKYO? COSCIENS Biopharma has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.34, meaning that its share price is 134% less volatile than the S&P 500. SummaryOKYO Pharma beats COSCIENS Biopharma on 10 of the 14 factors compared between the two stocks. Remove Ads Get COSCIENS Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CSCI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CSCI vs. The Competition Export to ExcelMetricCOSCIENS BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.12M$6.87B$5.61B$7.68BDividend YieldN/A2.79%5.33%4.02%P/E Ratio-0.257.3523.5018.55Price / Sales1.46208.36376.0088.66Price / CashN/A65.6738.1734.64Price / Book0.206.256.814.11Net Income-$16.55M$142.34M$3.20B$247.18M7 Day Performance-8.51%-8.43%-5.42%-4.05%1 Month Performance4.10%-9.99%-0.12%-6.41%1 Year PerformanceN/A-12.60%7.61%-2.08% COSCIENS Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CSCICOSCIENS BiopharmaN/A$2.95-3.1%N/AN/A$11.12M$7.60M-0.2520OKYOOKYO Pharma3.2068 of 5 stars$1.42+5.2%$7.00+393.0%-9.4%$48.05MN/A0.007Short Interest ↓News CoveragePositive NewsGap UpVRCAVerrica Pharmaceuticals4.1558 of 5 stars$0.52-6.4%$9.50+1,719.6%-92.7%$47.92M$7.57M-0.2940OTLKOutlook Therapeutics1.5538 of 5 stars$1.50-1.0%$10.20+582.3%-88.9%$47.87MN/A-0.2020Positive NewsATNMActinium Pharmaceuticals1.7557 of 5 stars$1.49-3.9%$7.40+396.6%N/A$46.48M$81,000.00-1.0730Analyst RevisionNews CoverageGap DownRPTXRepare Therapeutics3.3867 of 5 stars$1.08-3.6%$4.50+316.7%-77.7%$45.91M$53.48M-0.54180IBIOiBio0.5635 of 5 stars$4.63flat$4.30-7.1%+1.5%$45.72M$375,000.000.00100Positive NewsGap UpNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070KZRKezar Life Sciences4.1093 of 5 stars$6.16+4.6%$39.50+541.2%-45.4%$44.94M$7M-0.4760Earnings ReportShort Interest ↑Analyst RevisionSPROSpero Therapeutics4.306 of 5 stars$0.82-0.6%$5.00+511.6%-55.2%$44.57M$89.87M11.68150Earnings ReportHigh Trading VolumeCELUCelularity0.318 of 5 stars$1.87+2.7%N/A-66.1%$44.52M$48.20M0.00220Short Interest ↑ Remove Ads Related Companies and Tools Related Companies OKYO Competitors VRCA Competitors OTLK Competitors ATNM Competitors RPTX Competitors IBIO Competitors NBRV Competitors KZR Competitors SPRO Competitors CELU Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CSCI) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COSCIENS Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share COSCIENS Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
